Thorlef Spickschen
Chairman bij German Kidney Foundation
Profiel
Thorlef Spickschen is currently the Chairman of the German Kidney Foundation, Director at Biovision AG, Director at Innovation GmbH, and a Member-Supervisory Board at Ruprecht-Karls-Universität Heidelberg.
Previously, he served as Chairman & Chief Executive Officer at Knoll AG and BASF Pharma Ltd.
He was also the Chairman-Supervisory Board at Biotest AG, Chairman-Executive Board at Roche Diagnostics GmbH and Boehringer Mannheim GmbH, and Managing Director-Germany & Central Europe at Eli Lilly & Co. Additionally, he held positions as a Director at Pharmion Corp.
and Cytos Biotechnology AG.
Currently, he is an Independent Director at Clovis Oncology, Inc. Dr. Spickschen obtained a doctorate degree from Universität zu Köln.
Actieve functies van Thorlef Spickschen
Bedrijven | Functie | Begin |
---|---|---|
Biovision AG | Director/Board Member | 18-05-2010 |
Innovation GmbH | Director/Board Member | 18-05-2010 |
Ruprecht-Karls-Universität Heidelberg | Director/Board Member | 13-01-2011 |
German Kidney Foundation | Chairman | - |
Eerdere bekende functies van Thorlef Spickschen
Bedrijven | Functie | Einde |
---|---|---|
CLOVIS ONCOLOGY, INC. | Director/Board Member | 10-07-2023 |
BIOTEST AG | Chairman | 10-05-2012 |
Pharmion Corp.
Pharmion Corp. Pharmaceuticals: MajorHealth Technology Pharmion Corp. engages in the development and commercialization of products for the treatment of hematology and oncology patients. It has operations in Switzerland, Israel, and Philippines. The company was founded by Patrick J. Mahaffy in 1999 and is headquartered in Boulder, CO. | Director/Board Member | 07-03-2008 |
BASF Pharma Ltd.
BASF Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The private company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million. | Chief Executive Officer | 01-01-2001 |
Knoll AG
Knoll AG Pharmaceuticals: MajorHealth Technology Part of BASF SE, Knoll AG develops pharmaceuticals. The private company is based in Haren, Germany. | Chief Executive Officer | 01-01-2001 |
Opleiding van Thorlef Spickschen
Universität zu Köln | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
BIOTEST AG | Health Technology |
Bedrijven in privébezit | 10 |
---|---|
Pharmion Corp.
Pharmion Corp. Pharmaceuticals: MajorHealth Technology Pharmion Corp. engages in the development and commercialization of products for the treatment of hematology and oncology patients. It has operations in Switzerland, Israel, and Philippines. The company was founded by Patrick J. Mahaffy in 1999 and is headquartered in Boulder, CO. | Health Technology |
Knoll AG
Knoll AG Pharmaceuticals: MajorHealth Technology Part of BASF SE, Knoll AG develops pharmaceuticals. The private company is based in Haren, Germany. | Health Technology |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | Commercial Services |
Roche Diagnostics GmbH
Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the private company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999. | Commercial Services |
BASF Pharma Ltd.
BASF Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The private company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million. | Health Technology |
Biovision AG | |
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
Innovation GmbH | |
German Kidney Foundation | |
Boehringer Mannheim GmbH |